The Immuno-Oncology Clinical Network (IOCN) was founded in 2022 by Dr. Anna Olsson-Brown and a dedicated team of trustees, with a shared vision of enhancing the care of cancer patients receiving immunotherapy. The board of trustees identified the need for a strong multidisciplinary and multi-specialty community to better equip healthcare professionals in managing the complexities of immuno-oncology treatments, including the significant iatrogenic immune-related side effects that can arise. In Spring 2023, the IOCN became a registered charity in England and Wales (Charitable Number 1205140).

Mission Statement

The IOCN exists to:

• Provide vital support to healthcare professionals involved in delivering immuno-oncology therapies, enhancing patient care through clinical guidance, education and training, service development, policy, governance, and research initiatives.
• Promote and advance research and activities that expand the understanding and management of immuno-oncology treatments, including associated immune-related side effects.

"Our mission is to build a collaborative Immuno-Oncology (IO) community to improve patient outcomes. Immunotherapy has revolutionized cancer treatment, offering curative and palliative options, yet it comes with challenges. Immune-mediated side effects often limit its broader application. By supporting healthcare professionals, we aim to address these challenges and optimize care for patients on immunotherapy," said Dr. Anna Olsson-Brown, CEO of IOCN.

Education & Training

Recognizing the importance of education in managing immunotherapy’s unique toxicities, IOCN offers comprehensive training and resources for healthcare teams. Our educational videos cover a wide range of immune-related adverse events (irAEs), sharing case studies and evidence-based methods to ensure best practices in treatment.

Join us today and visit our Education Page to learn more.